Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Alpha Synuclein (SNCA) Drugs in Development Report Overview
Alpha-synuclein is a protein normally found in cells all over the body and is one of the key players in Parkinson’s disease. The Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) drugs in development research report provides comprehensive information on the therapeutics under development for Alpha Synuclein. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication.
The pipeline report covers the descriptive pharmacological action and product description of SNCA. It includes the complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in SNCA therapeutic development and features dormant and discontinued products.
Buy the Full Report to Know More about the SNCA Pipeline Products
| Key Therapy Areas | · Central Nervous System
· Metabolic Disorders · Cardiovascular · Gastrointestinal · Infectious Disease · Ophthalmology |
| Key Indications | · Parkinson’s Disease
· Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) · Lewy Body Dementia · Alzheimer’s Disease · Neurodegenerative Diseases |
| Key Mechanisms of Action | · Alpha Synuclein Inhibitor |
| Key Routes of Administration | · Oral
· Intravenous · Subcutaneous · Intrathecal · Nasal |
| Key Molecule Types | · Small Molecule
· Monoclonal Antibody · Gene Therapy · Fusion Protein · Antibody |
| Leading Companies | · AC Immune SA
· ABL Bio Inc · Alterity Therapeutics Ltd · Annovis Bio Inc · Aprinoia Therapeutics Inc |
| Enquiry & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
SNCA Pipeline Products Segmentation by Therapy Areas
The key therapy areas associated with SNCA drugs in development are the central nervous system, metabolic disorders, cardiovascular, gastrointestinal, infectious disease, and ophthalmology. The central nervous system therapy area had the highest share among SNCA drugs in development in 2022.
SNCA Pipeline Products Analysis by Therapy Areas, 2022 (%)
Buy the Full Report for More Therapy Area Insights into the SNCA Pipeline Products
SNCA Pipeline Products Segmentation by Indications
A few of the key indications for SNCA drug application include Parkinson’s disease, multiple system atrophy (MSA or Shy-Drager syndrome or multi-system degeneration), Lewy body dementia, Alzheimer’s disease, and neurodegenerative diseases, among others. Alpha Synuclein drugs had the highest number of products in development for Parkinson’s disease in 2022.
SNCA Pipeline Products Analysis by Indications, 2022 (%)
Buy the Full Report for More Indication Insights into SNCA Pipeline Products
SNCA Pipeline Products Segmentation by MoA and Molecule Types
The only mechanism of action in SNCA drugs in development is the Alpha Synuclein Inhibitor. A few of the key molecule types associated with SNCA pipeline drugs are small molecule, monoclonal antibody, gene therapy, fusion protein, and antibody. Among them, small molecule had the highest number in the pipeline in 2022.
SNCA Pipeline Products Analysis by Molecule Types, 2022 (%)
Buy the Full Report for More MoA and Molecule Types Insights into SNCA Pipeline Products
SNCA Pipeline Products Segmentation by Routes of Administration
The SNCA drugs can be administered by oral, intravenous, subcutaneous, intrathecal, and nasal routes. Oral RoA was the most preferred way for Alpha Synuclein drug administration in 2022.
SNCA Pipeline Products Analysis by Routes of Administration, 2022 (%)
Buy the Full Report for More RoA Insights into SNCA Pipeline Products
SNCA Pipeline Products - Competitive Landscape
AC Immune SA had the highest number of products in the SNCA pipeline in 2022
A few of the leading companies associated with SNCA pipeline products are:
- AC Immune SA
- ABL Bio Inc
- Alterity Therapeutics Ltd
- Annovis Bio Inc
- Aprinoia Therapeutics Inc
AC Immune SA: AC Immune is headquartered in Lausanne, Switzerland. It is a clinical-stage biopharmaceutical company that discovers, designs, and develops proprietary medicines to prevent, diagnose, and treat neurodegenerative diseases associated with protein misfolding. The company’s technology platforms help it to design, discover, and develop antibodies, small molecules, and vaccines.
SNCA Pipeline Products Analysis by Companies, 2022 (%)
Buy the Full Report for More Company Insights into SNCA Pipeline Products
SNCA Pipeline Products - Featured News
7th November 2022: Alterity Therapeutics is a biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases. It announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study. The presentation was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, 2022.
Buy the Full Report to Know More Featured News about SNCA Pipeline Products
Segments Covered in the Report
SNCA Pipeline Products Therapy Area Outlook (2022)
- Central Nervous System
- Metabolic Disorders
- Cardiovascular
- Gastrointestinal
- Infectious Disease
- Ophthalmology
SNCA Pipeline Products Indication Outlook (2022)
- Parkinson’s Disease
- Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
- Lewy Body Dementia
- Alzheimer’s Disease
- Neurodegenerative Diseases
SNCA Pipeline Products MoA Outlook (2022)
- Alpha Synuclein Inhibitor
SNCA Pipeline Products RoA Outlook (2022)
- Oral
- Intravenous
- Subcutaneous
- Intrathecal
- Nasal
SNCA Pipeline Products Molecule Type Outlook (2022)
- Small Molecule
- Monoclonal Antibody
- Gene Therapy
- Fusion Protein
- Antibody
Scope
- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA).
- The report reviews Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The report assesses Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The report reviews the latest news and deals related to Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) targeted therapeutics.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
AC Immune SA
Alterity Therapeutics Ltd
Annovis Bio Inc
Aprinoia Therapeutics Inc
Arvinas Inc
AstraZeneca Plc
AUM LifeTech Inc
BioArctic AB
Chimerna Therapeutics Inc
DegenRx BV
Denali Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Enterin Inc
Fulcrum Therapeutics Inc
Genmab AS
ICB International Inc
Ionis Pharmaceuticals Inc
ND Biosciences SA
Neuramedy Co Ltd
Neurimmune Holding AG
Neuropore Therapies Inc
nLife Therapeutics SL
Nuravax Inc
Prazer Therapeutics
Priavoid GmbH
Primary Peptides Inc
Proclara Biosciences Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
ResQ Biotech
Seelos Therapeutics, Inc.
Selonterra Inc
Shape Therapeutics Inc
Synapss Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Treventis Corp
UCB SA
UniQure NV
Vaxxinity Inc
Wren Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which was the leading therapy area in the SNCA drugs in development in 2022?
The central nervous system therapy area had the highest share among SNCA drugs in development in 2022.
-
Which was the leading indication in the SNCA drugs in development in 2022?
Alpha Synuclein drugs had the highest number of products in development for Parkinson’s disease in 2022.
-
Which was the leading RoA for the SNCA drugs in development in 2022?
Oral was the most preferred way for SNCA drug administration in 2022.
-
Which was the leading molecule type for the SNCA drugs in development in 2022?
Small molecule was the leading molecule type for the SNCA drugs in development in 2022.
-
Which are the leading companies associated with SNCA drugs in development?
A few of the leading companies associated with the SNCA pipeline products are AC Immune SA, ABL Bio Inc., Alterity Therapeutics Ltd, Annovis Bio Inc., and Aprinoia Therapeutics Inc., among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports